Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Nymox Pharm Corp

(NASDAQ: NYMX)
Add to Portfolio
-0.05 (-1.58%)
as of Feb 18, 2020

Last 3.12
Change -0.05 (-1.58%)
Open 3.15
Prev. Close 3.17
Today's Range
3.04
3.29
52wk Range
1.32
4.09
Volume 116,600
Avg Volume 278,670
Sector SIC-2835 In Vitro & In Vivo Diagnostic Substances

Perfomance Comparison

Name Today 3-Month 1-Year
NYMX -1.58% +69.57% +15.13%
DJIA -0.56% +5.72% +12.94%
S&P 500 -0.29% +8.27% +21.43%

Key Statistics

Annual EPS -0.21
Dividend Yield 0.00%
P/E Ratio N/A
Market Capitalization, $K 219,700
Weighted Alpha +61.40
Standard Deviation -0.24
Profit Margin -852.11%
Beta 1.81

Growth Rates

YTD +41.82%
1-Year +16.97%
3-Year -7.31%
5-Year +673.17%
10-Year -19.34%

Opinion

Sell Hold Buy

Recent Headlines

Nymox Announces New Appointment of Russell Thomson

GlobeNewswire via COMTEX - Thu Feb 06, 09:30AM EST
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce the new appointment of Russell I. Thomson PhD, FRSC to the position of Nymox Vice President of Quality and Regulatory Affairs. Dr Thomson is an authority in t(full story)
NYMX: 3.12 (-0.05)

Nymox Provides Update on Current Corporate Activities

GlobeNewswire via COMTEX - Tue Jan 28, 09:30AM EST
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide a current January 2020 update on several important corporate activities and achievements since the last update in October 2019.(full story)
NYMX: 3.12 (-0.05)

Nymox Announces New Peer Review Article on Fexapotide

GlobeNewswire via COMTEX - Mon Jan 06, 11:00AM EST
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to report a new peer review research report has been published on experimental studies of the Company's Fexapotide Triflutate treatment for prostate enlargement (BPH) and (full story)
NYMX: 3.12 (-0.05)

Nymox Reports on Newly Issued Patents and Corporate

GlobeNewswire via COMTEX - Mon Oct 21, 09:30AM EDT
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to report very positive fundamental news, that the Company has received several new additional United States, European, and other jurisdictional formal patent issuances co(full story)
NYMX: 3.12 (-0.05)

Nymox End of Q2 New Investor Presentation on Website

GlobeNewswire via COMTEX - Tue Jun 25, 11:45AM EDT
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide an up-to-date investor communication presentation posted on the Nymox website today as the end of second quarter update for shareholders. The new company presen(full story)
NYMX: 3.12 (-0.05)